Salesforce

Citigroup analyst Tyler Radke maintains Salesforce (NYSE:CRM) with a Neutral and raises the price target from $325 to $339.

Canaccord Genuity analyst David Hynes maintains Salesforce (NYSE:CRM) with a Buy and maintains $350 price target.

Veeva Systems (VEEV) cited “more optimism” among top pharmaceutical customers as macro hurdles persist, UBS Securities said Thursday in a report. Veeva’s outlook “hints at overall demand stabilization or perhaps a H2 improvement,” UBS said. “We expect the stock to find support given the green shoots of improvement and a likely upward revision” to the consensus for free cash flow, UBS said. Veeva’s plans to subsidize service costs associated with migration to the new Vault CRM product will lessen the risk of losing customers to Salesforce (CRM), UBS said. UBS reiterated its neutral rating on Veeva’s stock and kept the price target at $235. At least six other analysts raised their price targets after Veeva reported Q4 results Thursday that topped consensus estimates. Veeva shares fell 1% in recent Friday trading.

Salesforce (CRM) is poised to benefit “significantly” from its generative AI initiatives on the heels of “solid” fiscal Q4 results., Wedbush said Thursday in a report. “One of the biggest initiatives in the field is around monetizing the AI theme” in the “massive installed base,” Wedbush said. “We believe this is a major land grab opportunity that could significantly benefit [Salesforce] over the coming years and could increase overall revenue by $4 billion plus annually based on our estimates and field work by 2025.” Wedbush maintained its outperform rating on the stock and kept the price target at $325. “We continue to believe the risk/reward on [Salesforce] is compelling at current levels as the growth and margin story play out over the next 12 to 18 months,” Wedbush said. “The installed base opportunity is still underappreciated by the Street in our opinion as the [Salesforce] machine takes hold over the

Piper Sandler analyst Brent Bracelin maintains Salesforce with a Neutral and raises the price target from $285 to $300.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target to $330 from $300 on a P/E of 29.6x our CY 25 EPS view, within peers but well below historical. We increase our FY 25 (Jan.) EPS to $9.74 from $9.45 and keep FY 26 at $11.14. CRM posts Jan-Q EPS of $2.29 vs. $1.68, beating the $2.27 consensus. Sales rose 11%, near expectations, with subscription and support revenues +12% and professional services -9%. Despite a disappointing FY 24 revenue outlook that implies growth decelerating to 9%, we think CRM is setting the bar low given the lag effect of measured spending on the subscription side, but note bookings are improving. Importantly, EPS/FCF guide was above our view as CRM executes well on operating margins (seen expanding by 200 bps to 32.5%

The following is a summary of the Salesforce, Inc. (CRM) Q4 2024 Earnings Call Transcript: Financial Performance: Salesforce reported Q4 revenue of $9.3 billion, an 11% increase year over year, with full fiscal year revenue rising to $34.9 billion. Non-GAAP operating margin for Q4 was 31.4%, a rise of 220 basis points year over year. The company saw a full year non-GAAP operating margin of 30.5%. Operating cash flow for the fiscal year reached a record $10.2 billion. Remaining performance obligation (RPO) for Q4 sat at $56 billion, a 12% increase. The revenue attrition for the quarter was slightly above 8%, consistent with previous quarters. The company has projected a non-GAAP operating margin of 32.5% and GAAP operating margin of 20.4% for fiscal year 2025. Business Progress: There was strong growth seen in the public sector and travel transportation and hospitality sectors. Eight out of the top ten deals in

Piper Sandler analyst Brent Bracelin reiterates Salesforce (NYSE:CRM) with a Neutral and maintains $285 price target.

Salesforce Guides For Q1 Revenue of $9.12-$9.17 Billion, Vs CIQ Analyst Consensus of $9.14 Billion: FY 2025 Revenue Seen at $37.7-$38 Billion, Vs Consensus of $38.6 Billion.

Salesforce Share Repurchase Program Authorization Increased by $10 B.

Salesforce Sees FY24 Subscription & Support Rev Growth Guidance About 10% Y/Y.

Salesforce Inc (NYSE:CRM) reported fourth-quarter financial results Wednesday after the bell. Here’s a look at the key metrics from the quarter. Q4 Earnings: Salesforce’s fourth-quarter revenue increased 11% year-over-year to $9.29 billion, which beat the consensus estimate of $9.22 billion, according to Benzinga Pro. The company reported quarterly adjusted earnings of $2.29 per share, which beat analyst estimates of $2.26 per share. Operating margin came in at 17.5% for the fourth quarter. Cash flow from operations was up 22% year-over-year to $3.4 billion, and free cash flow was up 27% to $3.26 billion. The company ended the quarter with remaining performance obligations of $56.9 billion, up 17% year-over-year. Salesforce’s board declared its first-ever cash dividend of 40 cents per share, payable on April 11 to shareholders of record as of March 14. The company’s board also increased its share repurchase program by $10 billion. “With our trusted, unified Einstein 1 Platform, we’re